Technical Analysis for TSBX - Turnstone Biologics Corp.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 3.25 | 1.56% | 0.05 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 50 DMA | Bullish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Stochastic Reached Overbought | Strength | 0.00% | |
| Weak + Overbought | Other | 0.00% | |
| BB Squeeze + Upper Band Touch | Range Contraction | 0.00% | |
| BB Squeeze Started | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 23 hours ago |
| Rose Above 50 DMA | about 23 hours ago |
| Rose Above Previous Day's High | about 23 hours ago |
| 50 DMA Resistance | about 23 hours ago |
| Up 5% | about 23 hours ago |
Get a Trading Sidekick!
- Earnings date: 02/28/2024
Turnstone Biologics Corp. Description
Turnstone Biologics is a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by pioneering a differentiated approach to TIL therapy. Turnstone’s innovative TIL therapy is based upon the identification, selection, and expansion of the most potent tumor-reactive T cells, known as Selected TILs, and is designed to overcome the limitations of first-generation bulk TILs that have demonstrated objective responses only in limited tumor types. Turnstone’s most advanced program, TIDAL-01, is currently being evaluated in two Phase 1 studies in patients with melanoma, breast cancer, and colorectal cancer, and the Company is also actively advancing its preclinical pipeline programs including TIDAL-02, its next Selected TIL program, and its TIDAL-01 and viral immunotherapy combination program.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Solid Tumors Immunotherapy Breast Cancer Melanoma Colorectal Cancer Tumor Infiltrating Lymphocytes
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.2 |
| 52 Week Low | 1.625 |
| Average Volume | 174,883 |
| 200-Day Moving Average | 4.23 |
| 50-Day Moving Average | 3.16 |
| 20-Day Moving Average | 2.88 |
| 10-Day Moving Average | 2.83 |
| Average True Range | 0.33 |
| RSI (14) | 57.81 |
| ADX | 20.34 |
| +DI | 26.76 |
| -DI | 13.01 |
| Chandelier Exit (Long, 3 ATRs) | 2.89 |
| Chandelier Exit (Short, 3 ATRs) | 3.45 |
| Upper Bollinger Bands | 3.36 |
| Lower Bollinger Band | 2.40 |
| Percent B (%b) | 0.89 |
| BandWidth | 33.14 |
| MACD Line | -0.02 |
| MACD Signal Line | -0.07 |
| MACD Histogram | 0.0554 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.72 | ||||
| Resistance 3 (R3) | 3.72 | 3.55 | 3.64 | ||
| Resistance 2 (R2) | 3.55 | 3.43 | 3.56 | 3.62 | |
| Resistance 1 (R1) | 3.40 | 3.36 | 3.48 | 3.41 | 3.59 |
| Pivot Point | 3.24 | 3.24 | 3.28 | 3.24 | 3.24 |
| Support 1 (S1) | 3.09 | 3.12 | 3.16 | 3.09 | 2.91 |
| Support 2 (S2) | 2.92 | 3.04 | 2.93 | 2.88 | |
| Support 3 (S3) | 2.77 | 2.92 | 2.86 | ||
| Support 4 (S4) | 2.78 |
